{"id":118593,"date":"2021-03-27T16:40:54","date_gmt":"2021-03-27T16:40:54","guid":{"rendered":"https:\/\/precoinnews.com\/?p=118593"},"modified":"2021-03-27T16:40:54","modified_gmt":"2021-03-27T16:40:54","slug":"glaxosmithkline-requests-emergency-authorization-from-fda-for-covid-antibody-drug","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/business\/glaxosmithkline-requests-emergency-authorization-from-fda-for-covid-antibody-drug\/","title":{"rendered":"GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug"},"content":{"rendered":"
In this article<\/p>\n
GlaxoSmithKline and Vir Biotechnology on Friday applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.<\/p>\n
The companies are requesting clearance for use by high-risk people age 12 and older.<\/p>\n
The FDA submission is based on an interim analysis of a phase three trial that evaluated the drug for the early treatment of Covid-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from Covid by 85% compared with a placebo. The trial results were based on 583 patients.<\/p>\n
"As a result, the Independent Data Monitoring Committee recommended that the trial be stopped for enrolment due to evidence of profound efficacy," the companies said in a statement.<\/p>\n
The companies started testing the antibody on early-stage Covid patients in August, hoping to keep symptoms from progressing. Antibody drugs gained attention after they were used to treat former President Donald Trump last year.<\/p>\n
U.S. health officials say antibody drugs already authorized for use \u2013 from Regeneron and Eli Lilly \u2013 are being underutilized.<\/p>\n
GSK said the companies will also continue discussions with the European Medicines Agency and other global regulators to make the drug available to Covid patients as soon as possible.<\/p>\n
-Reuters contributed to this report.<\/em><\/p>\n